Cascadian Therapeutics Inc. clinical trials
Acquired by Pfizer, Dec 14, 2023 · source ↗
The registry lists 12 studies whose lead sponsor is Cascadian Therapeutics Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 29, 2018.
- 12studies on the registry
- 0open to participants now
Before and after it joined Pfizer
- First submitted before Cascadian Therapeutics Inc. became part of Pfizer
- 12
- First submitted after Cascadian Therapeutics Inc. became part of Pfizer
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Cascadian Therapeutics Inc.’s studies test, most studies first; none is open now — 5 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
All 12 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 208
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 1 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
- Cascadian Therapeutics Inc.12 studies
Something wrong with this grouping? Tell us on the Pfizer page.
Studies
Recruiting first, then most recently updated. Showing 12 of 12. All Pfizer studies →
- A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy ParticipantsCompletedNCT03758339Phase 1
Sponsor listed in the registry: Cascadian Therapeutics Inc. · First submitted before Cascadian Therapeutics Inc. became part of Pfizer
- Phase 1 Study of ONT-10 in Patients With Solid TumorsCompletedNCT01556789Phase 1
Sponsor listed in the registry: Cascadian Therapeutics Inc. · First submitted before Cascadian Therapeutics Inc. became part of Pfizer
- Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy VolunteersCompletedNCT01408316Phase 1
Sponsor listed in the registry: Cascadian Therapeutics Inc. · First submitted before Cascadian Therapeutics Inc. became part of Pfizer
- A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic CancerCompletedNCT00736372Phase 1
Sponsor listed in the registry: Cascadian Therapeutics Inc. · First submitted before Cascadian Therapeutics Inc. became part of Pfizer
- Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast CancerCompletedNCT02270372Phase 1
Sponsor listed in the registry: Cascadian Therapeutics Inc. · First submitted before Cascadian Therapeutics Inc. became part of Pfizer
- Phase I Trial of PX-478CompletedNCT00522652Phase 1
Sponsor listed in the registry: Cascadian Therapeutics Inc. · First submitted before Cascadian Therapeutics Inc. became part of Pfizer
- Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid TumorsCompletedNCT01978964Phase 1
Sponsor listed in the registry: Cascadian Therapeutics Inc. · First submitted before Cascadian Therapeutics Inc. became part of Pfizer
- Phase I Trial of Oral PX-866CompletedNCT00726583Phase 1
Sponsor listed in the registry: Cascadian Therapeutics Inc. · First submitted before Cascadian Therapeutics Inc. became part of Pfizer
- Study of PX-866 and Vemurafenib in Patients With Advanced MelanomaTerminatedNCT01616199Phase 1/2
Sponsor listed in the registry: Cascadian Therapeutics Inc. · First submitted before Cascadian Therapeutics Inc. became part of Pfizer
- Study of PX-866 and Docetaxel in Solid TumorsCompletedNCT01204099Phase 1/2
Sponsor listed in the registry: Cascadian Therapeutics Inc. · First submitted before Cascadian Therapeutics Inc. became part of Pfizer
- Phase II Study of PX-12 in Patients With Advanced Pancreatic CancerTerminatedNCT00417287Phase 2
Sponsor listed in the registry: Cascadian Therapeutics Inc. · First submitted before Cascadian Therapeutics Inc. became part of Pfizer
- Phase 1 and 2 Study of PX-866 and CetuximabCompletedNCT01252628Phase 1/2
Sponsor listed in the registry: Cascadian Therapeutics Inc. · First submitted before Cascadian Therapeutics Inc. became part of Pfizer